Jazz Pharmaceuticals plc

JAZZ

Held by 7 specialist biotech funds

High Convergence

7 funds opened new positions. Next phase2 readout (Glasdegib): Jun 2024. Short interest: 8.7% of float.

BiotechnologyCEO: Renee D. GalaIPO: 2007Website ↗

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Catalysts

Phase 3Q3 2002GW-1000-02Multiple SclerosisNCT01610700

Primary: Change From Baseline in Composite Primary Impairment Visual Analogue Scale Score at the End of 6 Weeks of Treatment (baseline and 6 weeks)Enrollment:160/160Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2002GW-1000-02Multiple SclerosisNCT01610713

Primary: Change From Mean Part A Primary Impairment Visual Analogue Scale Score (After 6 Weeks) at the End of Four Weeks of Open-label Treatment (10 Weeks Total) (End of Part A (week 6) - end of Part B (week 10 [4 weeks total open-label treatment]))Enrollment:154/154Sites: 1NA, TREATMENT

Phase 3PositiveQ3 2002GW-1000-02PainNCT01606189

Primary: Change From Baseline in the Mean Box Scale-11 Pain Review Score at the End of Each Treatment Period (Each Lasting 14-20 Days) (Up to 74 days)Enrollment:48/48Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2004Palliative Care, Pain, CancerNCT00674609

Primary: The Change in Mean Pain Numerical Rating Scale (NRS) Score From Baseline to the End of the Treatment. (2 weeks: baseline - end of week 2 (last 3 days of treatment))Enrollment:177/177Sites: 1RANDOMIZED, QUADRUPLE, SUPPORTIVE_CARE

Phase 3PositiveQ1 2004Sativex®Spasticity, Multiple SclerosisNCT00711646

Primary: Assessment of Change From Baseline in the Mean Spasticity 0-10 Numerical Rating Scale Score. (0-52 days)Enrollment:189/189Sites: 1RANDOMIZED, QUADRUPLE, SUPPORTIVE_CARE

Phase 3PositiveQ3 2004XyremNarcolepsyNCT00066170

Primary: Daytime Sleep Latency as Measured by the Maintenance of Wakefulness Test (MWT) (Baseline to Week 8)Enrollment:231/231Sites: 40RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q4 2004GW-1000-02Multiple Sclerosis, Spasticity, PainNCT01606137

Primary: Incidence of Adverse Events as a Measure of Subject Safety. (Up to 1051 days)Enrollment:507/507Sites: 1NA, TREATMENT

Phase 3Q1 2005GW-1000-02PainNCT01606202

Primary: Change From Baseline in Mean Central Neuropathic Pain 11-Point Numerical Rating Scale Scores at the End of Treatment (up to 51 Days). (Up to 51 days)Enrollment:116/116Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2005GW-1000-02Multiple Sclerosis, SpasticityNCT01610687

Primary: Incidence of Adverse Events as a Measure of Patient Safety (up to1206 days)Enrollment:137/137Sites: 1NA, TREATMENT

Phase 2PositiveQ2 2005Xyrem (sodium oxybate) oral solutionFibromyalgiaNCT00087555

Primary: The Primary Outcome Measure Was a Composite of Changes From Baseline in Three Co-primary Self Report Measures: Pain Visual Analog Scale (PVAS, Electronic Diaries), Fibromyalgia Impact Questionnaire (FIQ), and Patient Global Impression of Change (PGI-C). (Baseline to week 8)Enrollment:195/195Sites: 20RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q4 2005Sativex®Detrusor Overactivity, Multiple SclerosisNCT00678795

Primary: Change From Baseline in the Mean Daily Number of Incontinence Episodes at the End of Treatment (0 - 10 weeks)Enrollment:135/135Sites: 1RANDOMIZED, QUADRUPLE, SUPPORTIVE_CARE

Phase 3PositiveQ4 2005SativexMultiple SclerosisNCT01599234

Primary: Change From Baseline in Mean Spasticity 0-10 Numerical Rating Scale (NRS) Score During the Last 14 Day of Treatment (End of Treatment) (0-15 weeks)Enrollment:337/337Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2005experimental anti-anxiety drugAnxiety DisorderNCT00097708

Primary: Change in HAM-A Total Score (Baseline to week 8)Enrollment:511/511Sites: 50RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2006a benzodiazepine drugAnxiety DisorderNCT00106860

Primary: Assessment (over 37 additional weeks following the double-blind study) of the safety of the experimental drug in long-term use in subjects with Generalized Anxiety Disorder (GAD)Enrollment:Target 158Sites: 13NON_RANDOMIZED, TREATMENT

Phase 3Q2 2006SativexPain, Diabetic NeuropathyNCT00710424

Primary: The Change From Baseline in Mean Diabetic Neuropathy Pain 0-10 Numerical Rating Scale Score at the End of Treatment (Average of Last 7 Days Treatment) (Day 0 to Day 98)Enrollment:297/297Sites: 1RANDOMIZED, QUADRUPLE, SUPPORTIVE_CARE

Phase 3PositiveQ3 2006SativexPain, CancerNCT00675948

Primary: The Incidence of Adverse Events as a Measure of Subject Safety (0 - 657 days)Enrollment:43/43Sites: 1NON_RANDOMIZED, SUPPORTIVE_CARE

Phase 3Q4 2006SativexPain, Peripheral NeuropathyNCT00710554

Primary: Change From Baseline in Mean Peripheral Neuropathic Pain on a 0-10 Numerical Rating Scale (NRS) Score at the End of Treatment (15 Weeks) (Day 7 to Day 98)Enrollment:246/246Sites: 1RANDOMIZED, QUADRUPLE, SUPPORTIVE_CARE

Phase 3PositiveQ2 2007Sativex®Pain, Peripheral NeuropathyNCT00713323

Primary: Change From Parent Study Baseline in Mean Pain 0-10 Numerical Rating Scale (NRS) Score During the Last 4 Weeks of Open-label Treatment (38 weeks)Enrollment:380/380Sites: 1NA, SUPPORTIVE_CARE

Phase 3PositiveQ3 2007Sativex®Pain, Peripheral NeuropathyNCT00713817

Primary: Change From Baseline in Mean Daily Pain Severity on a 0-10 Numerical Rating Scale Score at the End of Treatment (Average of Last 7 Days Treatment) (Day 0-35)Enrollment:19/19Sites: 1RANDOMIZED, QUADRUPLE, SUPPORTIVE_CARE

Phase 2Q3 2008Sodium OxybateEssential TremorNCT00598078

Primary: Modified FTM(Fahn-Tolosa-Marin) Essentials Tremor Rating Scale, Sum of All Essential Rating Tremor Scales Including Voice Tremor (Hour 1)Enrollment:19/19Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2008ClonazepamEpilepsyNCT00594945

Primary: Number of Spikes and Sharp Waves, Relative Change From Baseline to Treatment Day (%). (Change from baseline to treatment day)Enrollment:45/45Sites: 6NON_RANDOMIZED, TREATMENT

Phase 2Q4 2008CPX-1 (Irinotecan HCl:Floxuridine) Liposome InjectionColorectal NeoplasmsNCT00361842

Primary: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 (From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months)Enrollment:65/65Sites: 13NON_RANDOMIZED, TREATMENT

Phase 3PositiveQ1 2009Sativex®Spasticity, Multiple SclerosisNCT00681538

Primary: The Change in Mean Spasticity Numerical Rating Scale (NRS) Score From Baseline to End of Treatment (Phase B). (Baseline (last 7 days of Week 4) - End of treatment (last 7 days of Week 17))Enrollment:572/572Sites: 1RANDOMIZED, QUADRUPLE, SUPPORTIVE_CARE

Phase 3PositiveQ1 2009SativexSpasticity, Multiple SclerosisNCT00702468

Primary: Number of Subjects Who Experience Treatment Failure. (Week 1- Week 5)Enrollment:36/36Sites: 1RANDOMIZED, QUADRUPLE, SUPPORTIVE_CARE

Phase 3PositiveQ2 2009FibromyalgiaNCT00423813

Primary: Pain VAS (Visual Analog Scale) Response. Percentage of Subjects With a Greater Than or Equal to 30% Reduction in Pain VAS From Baseline (BOCF). (Baseline to Week 14)Enrollment:573/573Sites: 116RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ3 2009Open-LabelChronic Obstructive Pulmonary DiseaseNCT00457951

Primary: Incidence of Treatment Failure (Time to hospital discharge and 21 days post-treatment, up to 31 days)Enrollment:158/158Sites: 38RANDOMIZED, DOUBLE, TREATMENT

Phase 2PositiveQ2 2010CPX-351Acute Myeloid LeukemiaNCT00788892

Primary: Number of Participants With Complete Remission (Within 6 weeks of the last induction treatment)Enrollment:126/126Sites: 28RANDOMIZED, TREATMENT

Phase 2PositiveQ4 2011CPX-351Acute Myeloid LeukemiaNCT00822094

Phase 2PositiveQ1 2012BrincidofovirCytomegalovirus InfectionNCT00942305

Phase 2Q2 2012GWP42003Dyslipidemias, Diabetes Mellitus, Type 2NCT01217112

Phase 2PositiveQ2 2012ADX-N05NarcolepsyNCT01485770

Phase 2NegativeQ4 2012Nab paclitaxelMetastatic Pancreatic CancerNCT01461915

Primary: Number of Patients who Achieved Progression-Free Survival (9 months)Enrollment:60/60Sites: 16RANDOMIZED, TREATMENT

Phase 2PositiveQ3 2013ADX-N05NarcolepsyNCT01681121

Phase 2ApprovedQ3 2013asparaginase Erwinia chrysanthemiAcute Lymphoblastic Leukemia, Lymphoblastic LymphomaNCT01643408

Primary: Two Day Nadir Serum Asparaginase Activity (NSAA) Level (48 hours post-dose 5)Enrollment:30/30Sites: 22NA, TREATMENT

Phase 3NegativeQ4 2014NabiximolsPain, Advanced CancerNCT01361607

Phase 2Q1 2015CMX001Ebola VirusNCT02271347

Phase 2Q1 2015GWP42003-P 5 mg/kg/day DoseEpilepsy, Dravet SyndromeNCT02091206

Phase 2PositiveQ2 2015CPX-351Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS)NCT02238925

Primary: Effect of CPX-351 on Cardiac Ventricular Repolarization (QTcF) (21 days)Enrollment:26/26Sites: 5NA, TREATMENT

Phase 2Q2 2015Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)NCT02150928

Phase 3NegativeQ3 2015NabiximolsPain, Advanced CancerNCT01424566

Phase 3PositiveQ4 2015GWP42003-P 20 mg/kg/day DoseEpilepsy, Dravet SyndromeNCT02091375

Phase 2Q4 2015BrincidofovirEbola Virus DiseaseNCT04268966

Phase 3Q4 2015BrincidofovirCMVNCT01769170

Primary: Number of Participants With Clinically Significant CMV Infection Through Week 24 Post-Transplant (24 weeks)Enrollment:452/452Sites: 43RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ4 2015CPX-351High Risk Acute Myeloid LeukemiaNCT01696084

Phase 3Q1 2016NabiximolsPain, Advanced CancerNCT01337089

Primary: Percent Of Participants With Treatment-emergent Adverse Events (Baseline, Day 183)Enrollment:660/660Sites: 128NA, TREATMENT

Phase 3NegativeQ1 2016BrincidofovirCytomegalovirus DiseaseNCT02439970

Primary: The Incidence of CMV Disease (52 weeks (± 28 days))Enrollment:5/5Sites: 3RANDOMIZED, TRIPLE, PREVENTION

Phase 2Q1 2016GWP42004Diabetes Mellitus, Type 2NCT02053272

Phase 3NegativeQ2 2016BrincidofovirAdenovirus InfectionNCT02087306

Phase 3PositiveQ3 2016DefibrotideHepatic Veno-Occlusive DiseaseNCT00628498

Primary: Survival by Day+100 Post Stem Cell Transplant or Chemotherapy (Day +100 from HSCT or 100 days from start of chemotherapy)Enrollment:1,206/1,206Sites: 125NA, TREATMENT

Phase 3Q3 2016SativexCerebral PalsyNCT01898520

Phase 3PositiveQ4 2016JZP-110Obstructive Sleep ApneaNCT02348619

Phase 3PositiveQ1 2017JZP-110NarcolepsyNCT02348593

Phase 3PositiveQ1 2017XyremNarcolepsy With CataplexyNCT02221869

Phase 2PositiveQ2 2017GWP42003-PEpilepsyNCT02564952

Phase 2Q2 2017CPX-351Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS)NCT02269579

Primary: Total Drug Plasma PK (Pre-dose and up to Day 21 during first induction only)0Sites: 5NA, TREATMENT

Phase 2Q3 2017GWP42006Epilepsy, Focal SeizuresNCT02365610

Phase 3Q4 2017JZP-110Narcolepsy, Obstructive Sleep ApneaNCT02348632

Primary: Change in Epworth Sleepiness Scale (ESS) Score (Start of randomized withdrawal phase to end of randomized withdrawal (2 weeks))Enrollment:645/645Sites: 80NA, TREATMENT

Phase 3PositiveQ2 2018GWP42003-PEpilepsy, Dravet SyndromeNCT02224703

Phase 2PositiveQ3 2018CX-8998Essential TremorNCT03101241

Phase 2Q3 2018JZP-110Excessive Sleepiness, Parkinson DiseaseNCT03037203

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Early Discontinuation (Up to Day 35)Enrollment:66/66Sites: 25RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q3 2018GWP42003-PEpilepsyNCT02607891

Phase 3PositiveQ1 2019GWP42003-PTuberous Sclerosis Complex, SeizuresNCT02544763

Phase 3PositiveQ1 2019JZP-258Narcolepsy With CataplexyNCT03030599

Phase 2NegativeQ2 2019BrincidofovirAdenovirusNCT03339401

Phase 2Q2 2019BrincidofovirAdenovirusNCT03532035

Phase 2Q2 2019JZP-110Narcolepsy, Excessive SleepinessNCT02806908

Phase 2Q2 2019GWP42003-PEpilepsyNCT02607904

Phase 2Q2 2019JZP-110Obstructive Sleep Apnea, Excessive SleepinessNCT02806895

Phase 2Q2 2019Dociparstat sodiumAcute Myeloid LeukemiaNCT02873338

Phase 2NegativeQ3 2019ONC201Multiple MyelomaNCT02863991

Phase 2Q2 2020DefibrotideGraft-versus-host Disease, Acute-graft-versus-host DiseaseNCT03339297

Phase 2NegativeQ2 2020GWP42006Autism Spectrum DisorderNCT03849456

Phase 3PositiveQ2 2020JZP-258Idiopathic HypersomniaNCT03533114

Phase 2NegativeQ3 2020DefibrotideDLBCL, Neurotoxicity SyndromesNCT03954106

Phase 2Q3 2020CX-8998Parkinson's Disease, TremorNCT03436953

Phase 3Q4 2020DefibrotideVeno-occlusive DiseaseNCT02851407

Phase 3NegativeQ1 2021GWP42003-PRett Syndrome, RTTNCT03848832

Primary: Change From Baseline in the Mean Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score at Week 24 for the 15 mg/kg/Day GWP42003-P Dose Level Compared With Placebo (Baseline; Week 24)Enrollment:29/29Sites: 26RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ2 2021GWP42003-PTuberous Sclerosis Complex, SeizuresNCT02544750

Phase 3Q2 2022NabiximolsSpasticity in Participants With Multiple SclerosisNCT04657666

Phase 3NegativeQ2 2022DociparstatAcute Myeloid LeukemiaNCT04571645

Phase 3Q3 2022IM JZP-458Acute Lymphoblastic Leukemia, Lymphoblastic LeukemiaNCT04145531

Phase 2NegativeQ4 2022Dordaviprone (ONC201)GliomaNCT03295396

Phase 2NegativeQ1 2023Dordaviprone (ONC201)Endometrial Cancer RecurrentNCT03485729

Phase 3Q1 2023NabiximolsPost-Traumatic Stress DisorderNCT04592159

Phase 2Q2 2023ZW25 (Zanidatamab)HER2+/HR+ Breast CancerNCT04224272

Phase 3NegativeQ3 2023GWP42003-PSeizures Associated With EMASNCT05288283

Phase 2Q4 2023JZP541Irritability Associated With Autism Spectrum Disorder, Autism Spectrum Disorder, ASDNCT05733390

Phase 2Q4 2023JZP150Post Traumatic Stress DisorderNCT05178316

Phase 2NegativeQ4 2023LurbinectedinAdvanced Solid Tumor, Metastatic Solid Tumor, Urothelial CancerNCT05126433

Phase 2Q2 2024JZP385Essential TremorNCT05122650

Phase 2Jun 30, 2024GlasdegibAcute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related ChangesNCT04231851

Primary: Percentage of Participants With Event-Free Survival at 6 Months (6 months)Enrollment:30/30Sites: 4NA, TREATMENT

Phase 3Jul 29, 2024AtezolizumabSmall-Cell Lung CancerNCT05091567

Primary: Randomized Phase: Independent Review Facility (IRF) - Assessed Progression Free Survival (PFS) (Up to 26 months)Enrollment:660/660Sites: 93RANDOMIZED, TREATMENT

Phase 2Sep 1, 2024Enasidenib MesylateRecurrent Acute Myeloid LeukemiaNCT03825796

Primary: Complete remission (CR)/CR with incomplete hematologic recovery (CRi) after induction therapy (Up to day 60)Enrollment:2/2Sites: 3NA, TREATMENT

Phase 2Sep 1, 2024DefibrotideCovid19NCT04652115

Primary: The rate of adverse event of special interest (bleeding and hypotension) (Up to 21 days)Enrollment:Target 42Sites: 1NA, TREATMENT

Phase 2Q4 2024Parkinson Disease, TremorNCT05642442

Phase 2Apr 10, 2025Liposome-encapsulated Daunorubicin-CytarabineAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Secondary Acute Myeloid LeukemiaNCT04269213

Primary: Complete Response Rate (Morphological Complete Remission [CR] and Incomplete Blood Count Recovery [CRi]) (At day 45)Enrollment:21/21Sites: 4NA, TREATMENT

Phase 2Jun 6, 2025Liposome-encapsulated Daunorubicin-CytarabineAcute Myeloid Leukemia, Myeloid NeoplasmNCT04195945

Primary: 3-month Overall Survival (OS) (Up to 3 months from date of start of protocol therapy)Enrollment:60/60Sites: 1RANDOMIZED, TREATMENT

Phase 2Aug 28, 2025CPX-351Myeloid NeoplasmNCT05656248

Primary: Composite complete remission (CR) rates after one or two courses of CPX-351 (After one or 2 course of CPX-351, no later than day 42 from the start of each course of chemotherapy)Enrollment:25/25Sites: 1NA, TREATMENT

Phase 2Q3 2025ZanidatamabHER2-expressing CancersNCT05027139

Phase 2Q2 2026NabiximolsGlioblastoma, Brain Tumor, CannabisNCT05629702

Primary: Overall survival time (OS) (Time in whole days from date of randomisation to the date of death from any cause, assessed at a minimum of 12 months..)Enrollment:Target 120Sites: 22RANDOMIZED, TRIPLE, TREATMENT

Phase 2Jun 30, 2026PaclitaxelGastroesophageal AdenocarcinomaNCT06043427

Primary: Progression-free survival (36 months)Enrollment:Target 168Sites: 18RANDOMIZED, TREATMENT

Phase 3Q3 2026ZanidatamabGastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal AdenocarcinomaNCT05152147

Primary: Progression-free survival (PFS) by BICR (Up to 2.5 years)Enrollment:920/920Sites: 227RANDOMIZED, TREATMENT

Phase 2Q3 2026LurbinectedinAdvanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma, Advanced LeiomyosarcomaNCT05099666

Primary: The maximum tolerated dose (MTD) of lurbinectedin with doxorubicin in participants with advanced soft-tissue sarcoma (21 Days)Enrollment:Target 62Sites: 6RANDOMIZED, TREATMENT

Phase 2Q4 2026CPX-351Acute Myeloid Leukemia (AML) in RemissionNCT04990102

Primary: Maximum tolerate dose (Phase 1) (1 cycle (28 day cycle))Enrollment:Target 24Sites: 3NA, TREATMENT

Phase 2Q4 2026ZanidatamabBreast Cancer, Gastric Cancer, Esophageal CancerNCT06695845

Primary: Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR (Up to 2.5 years)Enrollment:Target 200Sites: 28NON_RANDOMIZED, TREATMENT

Phase 2Q1 2027CannabidivarinAutism Spectrum DisorderNCT03202303

Primary: Aberrant Behavior Checklist-Irritability (ABC-I) Subscale (Change from Baseline to Week 12 (Change over 12 weeks))Enrollment:Target 100Sites: 2RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2027CytarabineAcute Myeloid LeukemiaNCT03897127

Phase 2Jul 30, 2027LurbinectedinEwing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric CancerNCT05918640

Phase 2Dec 1, 2027CBD Oral SolutionFragile X SyndromeNCT06261502

Phase 2Dec 15, 2027CBD Oral Solution (eCBD system Target)Fragile X SyndromeNCT06261450

Phase 3Q4 2027XywavNarcolepsy, Idiopathic HypersomniaNCT07625280

Phase 2Dec 31, 2027ONC201Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine GliomaNCT05009992

Phase 2Q1 2028ZanidatamabHER2-positive Breast Cancer, Breast CancerNCT07102381

Phase 2Q1 2028LurbinectedinRefractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing SarcomaNCT05734066

Phase 2Jan 31, 2028Asparaginase Erwinia chrysanthemiB Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic LeukemiaNCT06738368

Phase 2Q1 2028LurbinectedinExtensive-stage Small-cell Lung CancerNCT07459634

Phase 2Mar 13, 2028ZanidatamabNon-Small Cell Lung Cancer, Sarcoma, Head &Amp; Neck CancerNCT07192068

Phase 3Q2 2028ZanidatamabMetastatic HER2-positive Breast CancerNCT06435429

Phase 2Jun 1, 2028TislelizumabGastroesophageal AdenocarcinomaNCT07290985

Phase 3Q2 2028Dordaviprone (ONC201)H3 K27M, GliomaNCT05580562

Phase 3Q3 2028JZP926 capsuleJuvenile Myoclonic EpilepsyNCT07723963

Phase 2Aug 2, 2028Cytarabine and IdarubicinAcute Myeloid LeukemiaNCT05260528

Phase 3Q3 2028EverolimusDiffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Midline Glioma, H3K27-alteredNCT05476939

Phase 2Q4 2028JZP3507MeningiomaNCT07533942

Phase 3Q4 2028ZanidatamabBiliary Tract CancerNCT06282575

Phase 2Q4 2028ONC206Advanced Pheochromocytoma and Paraganglioma, PCPGNCT07282587

Phase 2Q1 2029ZanidatamabGastroesophageal Adenocarcinoma, First Line Therapy, HER2 + Gastric CancerNCT07176312

Phase 2Q2 2029LurbinectedinSmall Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung CancerNCT07153055

Phase 3Q3 2029CBD-OSDevelopmental and Epileptic Encephalopathy (DEE)NCT07723976

Phase 3Dec 1, 2029Cannabidiol (CBD)Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis, Clinical High Risk for Developing PsychosisNCT07434973

Phase 2Feb 28, 2030CannabidiolEarly Life Adversity, Trauma, StressNCT07278505

Jazz Pharmaceuticals plc

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research